IBL

Unique & Niche, Antibody & ELISA

IBL Newsletter
Spring 2022

Highlights – Gd-IgA1

Dear Valued Customers,
We hope this newsletter finds you well.
This newsletter focus about Gd-IgA1 which is a new biomarker of IgA Nephropathy.

Chronic Kidney Disease (CKD) is a progressive loss in kidney function and it affects 1 in 10 people around the world. Major causes of CKD are type 2 diabetic nephropathy, polycystic kidney disease and chronic glomerulonephritis. IgA nephropathy (IgAN) is the most common type of primary chronic glomerulonephritis.

Galactose-deficient IgA1 (Gd-IgA1) has been reported as a critical effector molecule in the pathogenesis and progression of IgAN and measuring Gd-IgA1 can replace biopsy.

Gd-IgA1revel in Serum



Novel ELISA Kit
Specifically detects Gd-IgA1 in Serum, EDTA-Plasma and Urine

The measuring system using snail (helix aspersa; HAA) lectin has been used in past numerous studies to detect serum levels of Gd-IgA1 in patients with IgAN. However, instability of glycan-recognizing activity, development of alternative measuring is desired.

Our ELISA kit (**Gd-IgA1 (Galactose-deficient IgA1) Assay Kit: #27600**), using monoclonal antibody (KM55) specifically recognizes galactose-deficient hinge sequence of human Gd-IgA1, is a lectin non-dependent measuring system that can quantitatively measure Gd-IgA1 in human serum, EDTA-Plasma and urine.

IHC application - Novel antibody (KM55)
Specifically stain IgAN

Monoclonal antibody (**Anti-Human Gd-IgA1(KM55) Rat IgG MoAb: #10777**) can detect Gd-IgA1 in tissue by IHC technique differently from the feature of HAA lectin and it has been revealed that Gd-IgA1 specifically exists in glomeruli of the patients of IgAN

IHC Protocol



Proceedings of 16th International Symposium on IgA Nephropathy IgA Nephropathy 2021 21–23 September 2021 (Virtual)

- IgAN: A South-Asian perspective (Page 5)
- What biomarkers are on the horizon that may help risk stratify patients with IgAN? (Page 45)
- Clinical significance of intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy. (Page 69)
- Relevance of serum Gd-IgA1 levels in South Asian IgAN- prospective longitudinal cohort (GRACE-IgANI). (Page 74)

IBL Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp URL: https://www.ibl-japan.co.jp/en/

LinkedIn